Kala Bio (KALA) Times Interest Earned (2016 - 2025)
Kala Bio (KALA) posted Times Interest Earned of -$17.78 for Q4 2025, down 136.56% sequentially from -$7.52 in Q3 2025, and down 161.69% YoY from $28.83 in Q4 2024.
Kala Bio (KALA) Times Interest Earned (2016 - 2025) Analysis & Trends
Kala Bio has reported Times Interest Earned for 10 years, with the latest figure at -$17.78 in Q4 2025.
- Quarterly Times Interest Earned fell 161.69% year-over-year to -$17.78 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$11.57 (down 57.8% YoY) and the FY2025 annual result came in at -$0.27, up 9.23% from the prior year.
- Times Interest Earned fell to -$17.78 in Q4 2025 per KALA's latest filing, from -$7.52 in the prior quarter.
- Over five years, Times Interest Earned peaked at -$6.01 in Q3 2023 and troughed at -$38.11 in Q4 2022.
- A 5-year average of -$11.63 and a median of -$9.86 in 2021 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2021 and 2023: Times Interest Earned tumbled 2390.72% in 2021, then soared 82.81% in 2023.
- Over 5 years, Times Interest Earned stood at -$21.77 in 2021, then slumped by 75.01% to -$38.11 in 2022, then jumped by 82.81% to -$6.55 in 2023, then decreased by 3.71% to -$6.8 in 2024, then plunged by 161.69% to -$17.78 in 2025.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$17.78, -$7.52, and -$10.2 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Kala Bio | 9.89 Mn | 9.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -17.78 |
| Sep 30, 2025 | -7.52 |
| Jun 30, 2025 | -10.20 |
| Mar 31, 2025 | -9.78 |
| Dec 31, 2024 | -6.80 |
| Sep 30, 2024 | -6.76 |
| Jun 30, 2024 | -6.59 |
| Mar 31, 2024 | -8.20 |
| Dec 31, 2023 | -6.55 |
| Sep 30, 2023 | -6.01 |
| Jun 30, 2023 | -6.79 |
| Mar 31, 2023 | -7.93 |
| Dec 31, 2022 | -38.11 |
| Sep 30, 2022 | -10.07 |
| Jun 30, 2022 | -11.77 |
| Mar 31, 2022 | -15.19 |
| Dec 31, 2021 | -21.77 |
| Sep 30, 2021 | -11.75 |
| Jun 30, 2021 | -13.10 |
| Mar 31, 2021 | -9.94 |